Morgan Stanley Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $769.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by investment analysts at Morgan Stanley from $768.00 to $769.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 1.83% from the company’s current price.

REGN has been the subject of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Scotiabank lifted their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Truist Financial reduced their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $789.95.

Regeneron Pharmaceuticals Trading Up 1.8%

REGN traded up $13.71 during trading on Monday, hitting $755.16. 311,870 shares of the company’s stock were exchanged, compared to its average volume of 890,090. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a 50 day moving average price of $758.39 and a 200 day moving average price of $651.29. The firm has a market cap of $79.37 billion, a P/E ratio of 18.17, a price-to-earnings-growth ratio of 1.92 and a beta of 0.40. The company has a current ratio of 4.77, a quick ratio of 4.22 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $12.07 EPS. As a group, analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Del Sette Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $2,253,000. Ashton Thomas Securities LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.4% during the fourth quarter. Ashton Thomas Securities LLC now owns 1,214 shares of the biopharmaceutical company’s stock valued at $938,000 after purchasing an additional 29 shares in the last quarter. Composition Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 8.0% in the fourth quarter. Composition Wealth LLC now owns 3,742 shares of the biopharmaceutical company’s stock worth $2,888,000 after purchasing an additional 276 shares during the period. Kornitzer Capital Management Inc. KS acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $1,460,000. Finally, PFA Pension Forsikringsaktieselskab acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $71,861,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $800 and moved to an “overweight” rating, signalling stronger buy-side conviction and a modest upside to the current price. Benzinga
• Positive Sentiment: Wells Fargo raised its price target to $800 (maintaining an “equal weight”), which supports the higher valuation range and adds momentum to the stock’s intraday gain. Benzinga
• Positive Sentiment: Regeneron reported Q4 2025 results that beat EPS and revenue estimates (EPS beat and modest revenue growth led by several key products), reinforcing the company’s cash flow profile and supporting the recent analyst optimism. Q4 earnings article
• Positive Sentiment: New presentations for EYLEA HD (aflibercept) at Angiogenesis 2026 — including final 64‑week QUASAR results and ELARA primary results — strengthen the drug’s clinical profile and could support long‑term ophthalmology revenue. GlobeNewswire
• Positive Sentiment: TD Cowen and other outlets have lifted targets and highlighted Regeneron’s dividend initiation and steady revenue growth discussed on the earnings call — added affirmation from sell‑side coverage. InsiderMonkey
• Neutral Sentiment: Truist slightly trimmed its target from $820 to $818 but kept a “buy” rating — a minor technical change that doesn’t alter broad buy-side sentiment. Benzinga TickerReport
• Neutral Sentiment: Market commentary pieces note a valuation gap and label REGN among “depressed” but potentially attractive names — useful for longer‑term investors but less of an immediate price catalyst. Yahoo Finance MSN
• Neutral Sentiment: Earnings call transcripts are available for deeper read on management commentary; these support the above themes but don’t add a new near‑term catalyst. Earnings transcript

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.